LabQ Clinical Exercise 15: Pharmacogenomic Testing for HIV-Positive Individuals

KRISTEN COFFEY, MS, MBCM (ASCP)

University of West Florida 

Pensacola, Florida

Primary Audience: Phlebotomists, Laboratory Technologists, Laboratory Directors

Secondary Audience: Pathologists, Clinical Scientists (Includes all sub-specialty areas), Students, Pathologist Assistants, Residents, and Students

Upon completion of this activity, you will be able to:

·         explain 2 factors that can contribute to virologic failure in treatment-experienced HIV-positive patients; 

·         differentiate virologic suppression from virologic failure using viral load thresholds;

·         describe different classes of antiretroviral medications used in HIV-positive patients to achieve virologic suppression;

·         predict how the mutations M184V, K103N/S, Y181 C/I/V, L76V, and E35D, will affect treatment outcomes in drugs targeted at reverse transcriptase and protease; and 

·         identify the polymorphism that predicts an adverse drug reaction with abacavir.